Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Friday, August 29, 2025 1 min read
Key Takeaway: Avadel Pharmaceuticals plc has announced its participation in several upcoming investor conferences. The company will provide live webcasts of these events, which will be available for 90 days afterward. Avadel is known for its innovative approach to medication development, particularly with its FDA-approved product, LUMRYZ™, for narcolepsy treatment.
Market Sentiment Analysis
POSITIVE FACTORS
Avadel Pharmaceuticals is actively engaging with investors.
The company showcases its commitment to transparency through webcasts.
LUMRYZ™ is a significant product addressing patient needs.
Full Press Release Details
DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website,investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visitwww.avadel.com.